VREOFOTCPharmaceutical PreparationsUS GAAP · USD

Vireo Growth Inc.

Vireo Growth Inc. is a U.S.-based cannabis company that cultivates, manufactures, distributes, and sells cannabis products through wholesale channels and owned or operated dispensaries. Its operations are concentrated in state-licensed markets across Maryland, Minnesota, Missouri, Nevada, New York, and Utah.

Revenue269m USD
+170.4 %y/y
Operating profit (EBIT)-1.0m USD
−107.7 %y/y
EBIT margin-0.4%
−14.0 ppy/y
Net income-68.1m USD
−143.2 %y/y
Free cash flow-24.6m USD
−12.2 %y/y

Fiscal year 2025 · change from previous year

Development 2020–2025

-1000100200300m USD2020: 49 m USD2020: EBIT -23 m USD20202021: 54 m USD2021: EBIT -20 m USD20212022: 75 m USD2022: EBIT -6.9 m USD20222023: 88 m USD2023: EBIT 11 m USD20232024: 99 m USD2024: EBIT 14 m USD20242025: 269 m USD2025: EBIT -1.0 m USD2025269-1.0
RevenueOperating profit (EBIT)

Business

Share of revenue
Cultivation25 %

Growing cannabis plants and producing raw material for downstream processing and sale.

Manufacturing20 %

Processing cultivated cannabis into finished products for wholesale and retail channels.

Wholesale25 %

Selling cannabis products to third-party dispensaries and other licensed buyers.

Retail Dispensaries30 %

Operating Green Goods and other dispensaries that sell directly to approved patients and adult-use customers.

Products

Reported · share of revenue
81.8%18.2%FY2025100 %
  • Retail81.8 %
  • Wholesale Product18.2 %

Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.

Customers

Vireo sells to two main customer groups: licensed third-party dispensaries in wholesale markets and end consumers who purchase through its owned or operated retail stores. Its retail customers include approved medical patients and adult-use consumers in the states where it operates, while wholesale customers buy finished cannabis products for resale.

Medical patients

Buy cannabis products through dispensaries for approved medical use and consistent product access.

Adult-use consumers

Purchase cannabis products at retail stores in states where adult-use sales are permitted.

Wholesale dispensaries

Buy cannabis products for resale in licensed third-party retail outlets.

Strategy

Vireo’s stated focus is on building a customer-centric cannabis platform across cultivation, manufacturing, wholesale, and retail. The company emphasizes operating in limited-license markets, using its dispensary network and state-licensed subsidiaries to control access to customers and product flow.

Deepen vertical integrationMedium term

Owning cultivation, manufacturing, wholesale, and retail improves control over supply and customer access.

Strengthen presence in limited-license marketsMedium term

Restricted licensing can support durable local market positions and distribution access.

Increase customer-centric retail executionShort term

Direct retail relationships can improve brand visibility and capture more end-market demand.

Geography

Vireo operates in six U.S. states: Maryland, Minnesota, Missouri, Nevada, New York, and Utah. Its retail footprint spans 36 dispensaries across these markets, while wholesale sales are concentrated in Maryland, Minnesota, and New York. The state-by-state structure matters because cannabis licensing, retail access, and market maturity vary materially by jurisdiction.

Risks

Vireo faces regulatory and licensing risk because cannabis operations depend on state approvals, local compliance, and market-specific rules. It also faces execution risk from operating across multiple states and business lines, plus industry-wide risks such as price pressure, product quality control, and changes in cannabis laws.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Regulatory approval risk for transactions and asset sales1Transaction completion risk2Multi-state operating complexity3Cannabis market competition and pricing pressure4
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Regulatory approval risk for transactions and asset salesImpact: HighLikelihood: Medium

    Cannabis assets often require government and regulatory consent before closing.

    Exposure: Asset Sale / RSA-related transactions

  2. Transaction completion riskImpact: HighLikelihood: Medium

    The company may not obtain approvals or satisfy conditions precedent, preventing expected benefits.

    Exposure: Acquisition / restructuring-related activity

  3. Multi-state operating complexityImpact: MediumLikelihood: Medium

    Different state rules, retail footprints, and wholesale channels increase operational complexity.

    ExposureMarylandMinnesotaMissouriNevadaNew YorkUtah
  4. Cannabis market competition and pricing pressureImpact: MediumLikelihood: Low

    Wholesale and retail cannabis markets can be fragmented and price competitive.

    Exposure: Wholesale and dispensary sales

Accounting

Judgemental items
Revenue recognition by channel

Wholesale and retail cannabis sales may be recognized at different points in the transaction cycle.

Impact: Affects quarterly comparability and reported revenue timing

Inventory valuation and adjustments

Cannabis inventory is subject to quality, yield, and obsolescence estimates.

Impact: Can change cost of sales and margin presentation

Stock-based compensation

The company has a large equity award base that creates recurring non-cash expense.

Impact: Affects operating expenses and adjusted earnings reconciliation

Debt extinguishment and interest expense

Financing actions can create large one-time charges and ongoing interest costs.

Impact: Can materially affect other expense and net income

Warrant fair value accounting

Changes in the value of held warrants can create non-operating gains or losses.

Impact: Introduces earnings volatility unrelated to core cannabis operations

Publicly listed companies with a comparable business focus.

Last updated: 24/09/2026